• home
  • contact
  • join us
  • About Us
  • Opportunity
  • Technology
  • Pipeline
  • Partners
  • Investors
  • News
About Us

We openly communicate our progress to enhance awareness of Avid?s activities in the research and business communities, as well as our prospects for external collaborations.

PRESS RELEASES

Avid to Present at Cowen and Company Healthcare Conference

Avid to Present at JPMorgan 28th Annual Healthcare Conference

Avid Radiopharmaceuticals to Present at Piper Jaffray 21st Annual Healthcare Conference

Avid Radiopharmaceuticals to Present at Oppenheimer 20th Annual Healthcare Conference on November 3rd

Avid Radiopharmaceuticals Expands Management Team to Support Alzheimer's

Philadelphia Retains More Than 40 Life Sciences and Alternative Energy Jobs As Two Science Center Companies Remain in City

Avid Radiopharmaceuticals Phase II Results Featured in Two Presentations at Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD)

CEO Dr. Daniel Skovronsky Named Ernst & Young Entrepreneur of The Year

Avid Radiopharmaceuticals to Present Clinical Trial Advances in Molecular Imaging of Alzheimer's

Avid Radiopharmaceuticals Closes $34.5 Million Series D Financing

Michael J. Fox Foundation Awards $1.9 Million for Development of Non-Invasive Neuroimaging Techniques In Living Brain

FDA Advisory Committee Provides Clear Path Forward For Development of Amyloid Imaging Agents For Alzheimer's

Avid Radiopharmaceuticals Presents Clinical Results of Novel Amyloid Imaging Agents at the 2008 International Conference on Alzheimer's

Avid Appoints Richard A. Baron as Chief Financial Officer

Phase I Data from Avid Radiopharmaceuticals, Inc.

Avid Radiopharmaceuticals Initiates First Phase II Trial of Novel Compound for Imaging Alzheimer's

Imaging Agent from Avid Radiopharmaceuticals to be Licensed by Bayer Schering Pharma for Early Detection of Alzheimer's Disease

Molecular Imaging of Diabetes Selected as 2007 Small Animal Image of the Year

Avid Radiopharmaceuticals Appoints Ernest Mario, Ph.D. to Board of Directors

Avid RP Closes $26 Million Series C Financing

MDS Nordion Enters Collaboration Agreement with Avid Radiopharmaceuticals on Imaging Compounds for Alzheimer's Disease

Avid Announces Results of AV-1 Molecular Imaging Agent for Alzheimer's Disease Presented at AD/PD Meeting

Schering AG and Avid Radiopharmaceuticals to develop novel approach for early diagnostic imaging of Alzheimer's Disease

Avid RP strengthens its drug and business development capabilities with the addition of three industry veterans

Avid RP Closes $8.9 Million Financing to Support Development of Alzheimer's Diagnostic and Prognostic Agents

Avid selected as Enterprise Award Finalist: Life Sciences Start-Up Company of the Year